Aclaris aims to raise $96 million through stock offering after shares soar
Aclaris Therapeutics has priced a planned $96 million stock sale, a day after shares of the firm soared to a nearly two-and-a-half-year high. The Wayne biopharmaceutical company's stock shot up more than 220% after it announced positive mid-stage clinical trial results for its experimental rheumatoid arthritis therapy. On Wednesday shares closed down 4.6% to $17.97 after earlier in the day being up by a much as 10%. Aclaris said it p lans to sell (NASDAQ: ACRS) nearly 5.5 million shares of its… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 21, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

Aclaris aims to raise $96 million through stock offering after shares soar
Aclaris Therapeutics has priced a planned $96 million stock sale, a day after shares of the firm soared to a nearly two-and-a-half-year high. The Wayne biopharmaceutical company's stock shot up more than 220% after it announced positive mid-stage clinical trial results for its experimental rheumatoid arthritis therapy. On Wednesday shares closed down 4.6% to $17.97 after earlier in the day being up by a much as 10%. Aclaris said it p lans to sell (NASDAQ: ACRS) nearly 5.5 million shares of its… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 21, 2021 Category: Biotechnology Authors: John George Source Type: news

SAVR an Option for Many Low-Risk Patients Excluded From Clinical Trials SAVR an Option for Many Low-Risk Patients Excluded From Clinical Trials
Many patients who are excluded from clinical trials comparing transcatheter aortic-valve replacement with surgical aortic-valve replacement appear to do well with the latter approach, according to researchers in Canada.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 20, 2021 Category: Surgery Tags: Cardiology News Source Type: news

Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in mice
(University of California - San Diego) UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 20, 2021 Category: Biology Source Type: news

Leveraging Predictive Dosing to Reduce Clinical Trial Risk, Upcoming...
In this free webinar, attendees will gain insight into the relationship between patient dosing patterns, intentional non-adherence and trial efficiency. The featured speakers will discuss best...(PRWeb January 20, 2021)Read the full story at https://www.prweb.com/releases/leveraging_predictive_dosing_to_reduce_clinical_trial_risk_upcoming_webinar_hosted_by_xtalks/prweb17670722.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 20, 2021 Category: Pharmaceuticals Source Type: news

Thoracic Chemotherapy May Advance Mesothelioma Treatment
Thoracic surgeon Dr. Marcello Migliore is convinced that adding hyperthermic intrathoracic chemotherapy to aggressive surgery can extend survival significantly for patients with pleural mesothelioma cancer. He wants others to know that, too. This seldom-used, controversial procedure, also known as HITHOC, involves circulating a heated, high-concentration chemotherapy solution throughout the chest cavity for 60 minutes immediately following aggressive mesothelioma surgery. The idea is to kill any microscopic tumor cells that evaded the surgeon, hopefully slowing a potential cancer recurrence. Unlike HIPEC, a similar procedu...
Source: Asbestos and Mesothelioma News - January 19, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

A clinical trial provides encouraging results on ivermectin for reducing mild COVID-19
(Barcelona Institute for Global Health (ISGlobal)) Results show a trend to lower viral loads and shorter duration of certain symptoms among treated patients, as compared to the placebo group (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 19, 2021 Category: International Medicine & Public Health Source Type: news

Ultra-small nanomedicines which stably deliver oligonucleotides to refractory cancers
(Innovation Center of NanoMedicine) Ultra-small nanomedicines with a size of ca. 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and oligonucleotide drugs. Chemically modified and double-stranded oligonucleotides dramatically enhanced the stability of the ultra-small nanomedicines in the bloodstream. The size allows for high permeability in cancer tissues by slipping through the cracks in tumor vasculatures and stromal tissues. Clinical trials and preclinical studies using the developed ultra-small nanomedicines are proceeding for refractory cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 19, 2021 Category: Cancer & Oncology Source Type: news

People with fever, pregnant and breastfeeding women avoid Covaxin, says Bharat Biotech
The vaccine maker in the fact sheet on Covaxin, posted in its website, said the clinical efficacy of the vaccine is yet to be established and is being studied in Phase 3 clinical trial and hence it is important to appreciate that receiving the vaccine does not mean other precautions related to COVID- 19 need not be followed. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 19, 2021 Category: Pharmaceuticals Source Type: news

Expert panel recommends permission for phase 1 clinical trial of Bharat Biotech's nasal vaccine
"Based on the safety and immunogenicity data of the phase 1 clinical trial, the company would be given permission for conducting phase 2 clinical trial," an official said on the condition of anonymity. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 19, 2021 Category: Pharmaceuticals Source Type: news

Sinovac says its COVID-19 vaccine more effective with longer dosing interval
China's Sinovac Biotech said on Monday that a clinical trial in Brazil showed its COVID-19 vaccine was almost 20 percentage points more... (Source: Reuters: Health)
Source: Reuters: Health - January 18, 2021 Category: Consumer Health News Source Type: news

Green med diet cuts non-alcoholic fatty liver disease by half - Ben-Gurion U. study
(American Associates, Ben-Gurion University of the Negev) Overall, the green MED diet produced dramatic reductions in fatty liver. NAFLD prevalence dropped from 62% at baseline to 31.5% in the green Mediterranean group, down to 47.9% in the Mediterranean group and 54.8% in the healthy dietary regimen group. Addressing this common liver disease by targeted lifestyle intervention might promote a more effective nutritional strategy. This Ben-Gurion University of the Negev clinical trial demonstrates an effective nutritional tool for NAFLD beyond weight loss (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 18, 2021 Category: Biology Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

New Hope Against Diseases Marked by Progressive Scarring of Lung Tissue
FRIDAY, Jan. 15, 2021 -- An inhaled medication might make every day physical activity a bit easier for patients with serious scarring of the lungs, a new clinical trial finds. The study, published online Jan. 13 in the New England Journal of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 15, 2021 Category: General Medicine Source Type: news

COVID Vaccine Questions Answered: Can You Still Catch Virus After First Dose?
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p0").init({"mcp":"cbs","width":"100%","height":"100%","video":"5196496","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p0","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 15, 2021 Category: Consumer Health News Authors: Health – CBS Boston Tags: Around the Nation Health News Dr. Mallika Marshall Dr. Max Gomez Norm Elrod Vaccination Source Type: news

Moderna Needs More Kids for COVID-19 Vaccine Trials Moderna Needs More Kids for COVID-19 Vaccine Trials
Moderna probably will not have clinical trial results anytime soon on how its COVID-19 vaccine affects children and adolescents, according to the company CEO and a federal official.WebMD Health News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - January 15, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Tuberculosis Kills As Many People Each Year As COVID-19. It ’ s Time We Found a Better Vaccine
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post Tuberculosis Kills As Many People Each Year As COVID-19. It’s Time We Found a Better Vaccine appeared first on Inter Press Service. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - January 15, 2021 Category: International Medicine & Public Health Authors: External Source Tags: Global Headlines Health TerraViva United Nations tuberculosis Source Type: news

Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralising COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection. (Source: World Pharma News)
Source: World Pharma News - January 15, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

New England Journal of Medicine publishes COVID-19 treatment trial results
A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine. (Source: World Pharma News)
Source: World Pharma News - January 15, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

‘This is about building trust’: Why Howard University is joining Novavax’s Covid vaccine trial
The D.C. academic institution and medical center has signed on as a clinical trial site for the company ’s late-stage study of its vaccine candidate. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 14, 2021 Category: Biotechnology Authors: Sara Gilgore Source Type: news

In lab study, nanoparticle shows promising results for treating severe allergies
For about 1 in 13 children in the U.S., usually harmless foodstuffs such as milk, eggs and peanuts can send the body ’s natural defenses into overdrive.Symptoms of food allergies can vary widely, but at worst, a systemwide allergic response can lead to anaphylaxis, a life-threatening condition characterized by a sudden drop in blood pressure and difficulty breathing.Although there are now some preventive measures for food-induced anaphylaxis, there are not yet any long-lasting solutions — treatments capable of locking the immune system into a state of tolerance, so that it doesn’t respond to allergens.Now...
Source: UCLA Newsroom: Health Sciences - January 14, 2021 Category: Universities & Medical Training Source Type: news

Arthritis drugs effective in improving survival in sickest COVID-19 patients, NIHR
Results from the REMAP-CAP clinical trial evaluated the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU). Patients receiving tocilizumab and a second drug called sarilumab - both types of immune modulators - have a significant impact on patient survival and can reduce the relative risk of death by 24% when administered to patients within 24 hours of entering intensive care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 14, 2021 Category: Consumer Health News Source Type: news

Executive Voice: He sees growth in a virtual world with Durham firm
CEO Paul Evans has guided Velocity Clinical Research through the pandemic as the clinical trial sector was forced to adapt fast and at large scale. Evans says the pandemic also has shown the necessity for improving the industry. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 14, 2021 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

DDT COA #000102: Physical Activity Accelerometry Assessment for Analgesic Clinical Trials (PAACT)
Clinical Outcome Assessments (COA) Qualification Submissions Office of Drug Evaluation (ODE) II Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 14, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

How the Oxford-AstraZeneca covid-19 vaccine was made, BMJ
This interview with Andrew Pollard, lead for the Oxford vaccine clinical trials in the UK, Brazil, and South Africa highlights how the Oxford vaccine was developed, how dosing was determined, and whether it will be effective for the new variants. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 14, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson ’s 1-Shot COVID-19 Vaccine Shows Promise in Early-Stage Trials
Johnson & Johnson’s experimental one-shot Covid-19 vaccine generated a long-lasting immune response in an early safety study, providing a glimpse at how it will perform in the real world as the company inches closer to approaching U.S. regulators for clearance. More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report, and all participants formed the antibodies within 57 days. The immune response lasted for the full 71 days of the trial. “Looking at the antibodies, there should be good hope and good reason that the va...
Source: TIME: Health - January 14, 2021 Category: Consumer Health News Authors: Riley Griffin / Bloomberg Tags: Uncategorized COVID-19 overnight wire Source Type: news

Comparing reactions of flu vaccines in older adults
(JAMA Network) Researchers in this randomized clinical trial compared injection-site pain and other reactions among adults age 65 and older who received flu vaccines. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 14, 2021 Category: International Medicine & Public Health Source Type: news

MicroRNA may serve as therapeutic targets for traumatic brain injury
(Walter Reed Army Institute of Research) WRAIR scientists have shown that traumatic brain injury causes coordinated microRNA dysregulation followed by increased amounts of the beta-site amyloid cleaving enzyme, or BACE1, and loss of amyloid precursor protein. BACE-1 cleaves APP to generate amyloid beta peptides, a hallmark of neurodegenerative disease pathology and brain cells loss, which are the focus of several clinical trials for Alzheimer's disease. Future research will characterize the direct role of miRNAs and their relationship to BACE1 within TBI. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 14, 2021 Category: International Medicine & Public Health Source Type: news

Study demonstrates efficacy of new treatment for neurofibromatosis type 1-related tumors
(Children's Hospital of Philadelphia) Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1). The results of the Phase 2 clinical trial, co-chaired by Michael J. Fisher, MD at CHOP, were published recently in Nature Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 14, 2021 Category: International Medicine & Public Health Source Type: news

India to treat homegrown COVID-19 vaccine same as AstraZeneca's
Administering Bharat Biotech's COVAXIN, a move cheered by nationalist politicians, has worried some health experts who consider it rushed, as the vaccine has only limited, "clinical-trial mode" approval. In addition to efficacy concerns, the close monitoring required for its use will be a massive challenge in a country of 1.35 billion people. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 14, 2021 Category: Pharmaceuticals Source Type: news

Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat...
Initiation of a Phase 1 clinical trial of VLX-1005(PRWeb January 14, 2021)Read the full story at https://www.prweb.com/releases/veralox_therapeutics_announces_ind_submission_for_vlx_1005_to_treat_heparin_inducted_thrombocytopenia/prweb17657995.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 14, 2021 Category: Pharmaceuticals Source Type: news

Helixmith announces the development of botanical therapeutic product...
Helixmith announces encouraging animal model efficacy data has been published in the Journal of Ethnopharmacology for their botanical therapeutic product for respiratory diseases. A clinical trial of...(PRWeb January 14, 2021)Read the full story at https://www.prweb.com/releases/helixmith_announces_the_development_of_botanical_therapeutic_product_for_respiratory_diseases_tadios/prweb17651354.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 14, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson's One-Dose COVID-19 Vaccine Promising in Early Trial
WEDNESDAY, Jan. 13, 2021 -- A single-shot COVID-19 vaccine from Johnson& Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts. The vaccine produced an immune... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 13, 2021 Category: General Medicine Source Type: news

Johnson & Johnson's One-Dose COVID Vaccine Promising in Early Trial
WEDNESDAY, Jan. 13, 2021 -- A single-shot COVID-19 vaccine from Johnson& Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts. The vaccine produced an immune... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 13, 2021 Category: General Medicine Source Type: news

J & J's one-shot Covid vaccine is safe and generates promising immune response in early trial
The new clinical trial data shows a single shot of the vaccine "gives sustainable antibodies," Dr. Paul Stoffels, J&J chief scientific... (Source: Reuters: Health)
Source: Reuters: Health - January 13, 2021 Category: Consumer Health News Source Type: news

Mortality Higher in Real-World LVAD Recipients Ineligible for Clinical Trials Mortality Higher in Real-World LVAD Recipients Ineligible for Clinical Trials
Roughly half of patients with advanced heart failure who receive a left ventricular assist device (LVAD) in clinical practice do not meet eligibility criteria for the clinical trials that led to expanded LVAD use, a new study suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 13, 2021 Category: Surgery Tags: Cardiology News Source Type: news

Labor Induction at 41 Weeks Tied to Lower Morbidity, Mortality Than Expectant Management Labor Induction at 41 Weeks Tied to Lower Morbidity, Mortality Than Expectant Management
Inducing labor at 41 weeks may result in a lower risk of severe adverse perinatal and neonatal outcomes than expectant management until 42 weeks, a systematic review and meta-analysis of randomized clinical trials in PLOS Medicine suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Johnson & Johnson Expects Covid Vaccine Results Soon but Lags in Production
The U.S. needs J.&J. ’s one-shot vaccine more than ever. But the company is behind on manufacturing promises made in its Operation Warp Speed contract. (Source: NYT Health)
Source: NYT Health - January 13, 2021 Category: Consumer Health News Authors: Carl Zimmer, Sharon LaFraniere and Noah Weiland Tags: Clinical Trials Coronavirus (2019-nCoV) Vaccination and Immunization Factories and Manufacturing Johnson & your-feed-healthcare Public-Private Sector Cooperation Disease Rates Research Source Type: news

Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001. VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. (Source: World Pharma News)
Source: World Pharma News - January 13, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

COMBINEDBrain receives grant from The Marlene and Spencer Hays Foundation
(COMBINEDBrain, Inc) Fulfilling the goal of promoting innovations in health care, The Marlene and Spencer Hays Foundation awarded COMBINEDBrain a grant of $68,000 which will be used for operating expenses to support 21 patient advocacy organizations prepare for clinical trials. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 13, 2021 Category: International Medicine & Public Health Source Type: news

DOD funding helps expand study of investigational drug to prevent ARDS in COVID
(University of Texas Health Science Center at Houston) Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at UTHealth. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 13, 2021 Category: Biology Source Type: news

Caries arrest effectiveness of silver diamine fluoride compared to alternative restorative technique: randomized clinical trial
Original Scientific ArticlePublished:02 January 2021European Archives of Paediatric Dentistry (2021)AbstractObjectiveThis RCT study assessed and compared the effect of a biannual application of 38% silver diamine fluoride (SDF) with alternative restorative technique (ART) on arresting caries in primary dentition.MethodsThe RCT was conducted over a period of 12 months and included 79 healthy children (237 primary teeth), aged 3 –8 years, selected from the University Pediatric Dentistry outpatient clinics, with at least one primary asymptomatic tooth with active dentinal occlusal/labial lesions. Childr...
Source: Dental Technology Blog - January 13, 2021 Category: Dentistry Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

WCCT Global Expands Clinical and Lab Services Capacity to Meet...
WCCT Global, Inc., a Contract Research Organization, or CRO, specializing in early phase clinical trials, is expanding its Orange County based clinical pharmacology unit and laboratory capacity to...(PRWeb January 13, 2021)Read the full story at https://www.prweb.com/releases/wcct_global_expands_clinical_and_lab_services_capacity_to_meet_increasing_demand_for_phase_1_and_covid_19_vaccine_clinical_trials/prweb17651032.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 13, 2021 Category: Pharmaceuticals Source Type: news

Combination treatment for methamphetamine use disorder shows promise in NIH study
Combination medication may be effective in treating adults with methamphetamine use disorder (Source: NIDA News)
Source: NIDA News - January 13, 2021 Category: Addiction Tags: Clinical Trials Network, News Release, Illicit Stimulants, Methamphetamine, NIDAMED News, Researchers, Treatment Research, Addiction Science Source Type: news

OpenClinica featured in televised " In Depth " educational...
OpenClinica is showcasing clinical trials and the technology that enables safe and effective vaccines, medications, and medical devices on the public television series, In Depth.(PRWeb January 13, 2021)Read the full story at https://www.prweb.com/releases/openclinica_featured_in_televised_in_depth_educational_series_showcasing_clinical_trial_technology/prweb17653622.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 13, 2021 Category: Pharmaceuticals Source Type: news

Un estudio de los Institutos Nacionales de la Salud (NIH) identifica promisorio tratamiento combinado para el trastorno por consumo de metanfetamina
Combination medication may be effective in treating adults with methamphetamine use disorder (Source: NIDA News)
Source: NIDA News - January 13, 2021 Category: Addiction Tags: Clinical Trials Network, News Release, Illicit Stimulants, Methamphetamine, NIDAMED News, Researchers, Treatment Research, Addiction Science Source Type: news

Experimental Drug for Alzheimer Disease Shows Promise
TUESDAY, Jan. 12, 2021 -- Drug maker Eli Lilly on Monday announced promising results from a small study of an experimental Alzheimer disease drug called donanemab. The two-year, phase 2 clinical trial included 272 patients with mild-to-moderate... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Roche confirms US government agreement to purchase additional doses of Regeneron ’s casirivimab and imdevimab
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of Regeneron ’s casirivimab and imdevimab antibody cocktail for use in non-hospitalised COVID-19 patients as part of Operation Warp Speed. The US government said it will provide these additional doses at no cost to patients, though healthcare facilities may charge fees related to administration, and will conti nue to coordinate allocation of the antibody cocktail to state and territorial health departments. Under the...
Source: Roche Media News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Roche confirms US government agreement to purchase additional doses of Regeneron ’s casirivimab and imdevimab
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase additional supply of Regeneron ’s casirivimab and imdevimab antibody cocktail for use in non-hospitalised COVID-19 patients as part of Operation Warp Speed. The US government said it will provide these additional doses at no cost to patients, though healthcare facilities may charge fees related to administration, and will conti nue to coordinate allocation of the antibody cocktail to state and territorial health departments. Under the...
Source: Roche Investor Update - January 12, 2021 Category: Pharmaceuticals Source Type: news